Anavex Life Sciences Corp (AVXL)

[Hosai]

Donnenamab had 3 brain bleed deaths directly related to drug (16 deaths in total in drug group including those not related to drug from n853 who started on the drug). Also 13 dosed particiants had serious symptoms relating to brain swelling. This still got FDA approved though.

Blarcamsine had 1 death not related to drug out of n 335 who started on the drug. Would rather have the dizziness and slightly higher drop out rate at the beginning then potential brain bleed.

The drop out rate for blarcamesine clearly diminshed as time went on for those on the drug with no drop outs between weeks 36 and 48 even for 50mg group. So those who were happy to stay on the drug clearly benefited versus those still on placebo. Also it sounds like from the presentation that they have had better success with nighttime dosage.